Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Oct 11, 2022 8:00pm
118 Views
Post# 35018489

RE:RE:RE:RE:RE:RE:“Low dose docetaxel”

RE:RE:RE:RE:RE:RE:“Low dose docetaxel”I don't know how often I will have to repeat it, it is not clear what this 11% of free docetaxel value they published mean. Is it AUC (area under the curve) which qhantifies the total docetaxel released in the blood stream over time or is it Cmax, which is maximum concentration of docetaxel reached in the bloodstream after injection. If it's AUC, it is unlikely that it would generate efficacy, if it's Cmax, then it would be another story. Again. Even if the concept would not work, i.e: TH1902 is not entering inside sortilin expressing cells or any other cells, it would still act as a slow release system for docetaxel with slow enzymatic cleavage of the linker by enzymes called esterases (able to cleave ester bonds, which is the nature of the chemical bond between the linker and docetaxel). So they really need to give clarity on that aspect and stop publishing vague stuff as if only scientific illiterates were reading them.

Wino115 wrote: Clearly not 11% free dox floating around did that. 


<< Previous
Bullboard Posts
Next >>